Hypertension in older diabetic patients

Jain, Navjot; Abe, Chikara; Goel, Anuj

doi:10.1002/9781118954621.ch23

Cited by 1 publication

(4 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapeutic management of the same involves use of one or more drugs at the same time, such as antidiabetic, antihypertensive, non steroidal anti-in ammatory drugs, antihyperlipidemic andantiulcers, etc. (Fawzy et al, 2015;Jain et al, 2017). METF plus TELMI is one of the most widely prescribed combinations (Fawzy et al, 2015;Jain et al, 2017).…”

Section: Sample Preparation and Methods Developmentmentioning

confidence: 99%

“…(Fawzy et al, 2015;Jain et al, 2017). METF plus TELMI is one of the most widely prescribed combinations (Fawzy et al, 2015;Jain et al, 2017). Considering this, there is a need of a very selective, sensitive, and simple assay method for detection of METF & TELMI from biological matrix having other interfering analytes (Fawzy et al, 2015).…”

Section: Sample Preparation and Methods Developmentmentioning

confidence: 99%

“…IDF has also reported that nearly half (46%, 415 million) of the adult population is living with diabetes, among them almost 90% are having type 2 diabetes (T2DM). It has been found that 40-60% of diabetic individuals develop hypertension as a comorbidity (Jain et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

“…The therapeutic management of metabolic syndrome is a challenge and initially involves diet-life style modi cation, and when this proven insu cient, then each confounding factor of the metabolic syndrome is treated with medicines (Fawzy et al, 2015;Jain et al, 2017). The rst line agent to treat diabetes and particularly in an obese patient is metformin.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effect of Diabetes mellitus on pharmacokinetics of metformin and telmisartan by using novel HPLC-UV method: A drug-disease interaction study

Borse

Upadhyay²,

Shama³

et al. 2022

Preprint

View full text Add to dashboard Cite

Metformin and Telmisartan are commonly co-prescribed drugs in diabetes plus hypertensive patients. Diabetes caused pharmacokinetic alterations in metformin due to alterations in drug metabolizing enzymes (DMEs) and/or transporters. But, there are no such reports for telmisartan alone or with metformin. Considering this, a simple, precise, robust, specific, and sensitive RP-HPLC method for simultaneous quantification of metformin and telmisartan in rat plasma were developed. Chromatographic separation achieved on cyano column with mobile phase consisting acetonitrile:10mM KH2PO4, pH 4.5 (60:40). Flow rate was 1.0mL/min. Detection wavelength was 237nm. The protein precipitation of both drugs from rat plasma was done using acetonitrile (recoveries ≥ 80%). HPLC bioanalytical calibration curve was found linear in the range of 10-3200ng/mL. Parameters like precision, accuracy, and stability were within accepted criteria for biomedical analysis. The developed method was successfully used for pharmacokinetic studies in normal and diabetic rats. Metformin (50mg/kg, p.o.; b.i.d.) and telmisartan (4mg/kg, p.o.; o.d.) were administered simultaneously. Diabetes significantly increased systemic exposure (increased AUC0 − t, Cmax; decreased CL, Vd) of metformin and telmisartan. This may be because of diabetes mediated increased SERT expression, decreased CYP2C11 and UGTs expression. Important to note that telmisartan doesn’t cause metformin PK alterations and vice-versa, in diabetic and normal rats.

show abstract